Cochrane · systematic review · CD012929
Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents, for people with asthma
Gallagher, A, Edwards, M, Nair, P, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
13
current version
GRADE rated
12
No studies
1
Included studies
NR
No studies 1 · 7.7%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 30.8%Moderate 5 · 38.5%High 3 · 23.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Anti‐IL13 or anti‐IL4 agents compared to placebo for children and adults with asthma
Population: children and adults with asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Exacerbation requiring hospitalisation or ED visit Anti‐IL13 or anti‐IL4 agents vs placebo | Rate ratio 0.68 [0.47, 0.98] | 2 studies · 2039 participants | Moderate Downgraded: imprecision, inconsistency, indirectness |
Health‐related quality of life (AQLQ) Scale: 1 to 7 (higher is better) Anti‐IL13 or anti‐IL4 agents vs placebo | no estimate extracted | 7 studies · 4960 participants | High |
Serious adverse events Anti‐IL13 or anti‐IL4 agents vs placebo | OR 0.91 [0.76, 1.09] | 22 studies · 7739 participants | Moderate Downgraded: imprecision, inconsistency, indirectness |
Exacerbation requiring OCS (rate ratio) Anti‐IL13 or anti‐IL4 agents vs placebo | RR 0.98 [0.72, 1.32] | 1 study · 452 participants | Low Downgraded: imprecision, inconsistency, indirectness |
Change from baseline in ACQ score Scale: 0 to 6 (higher is worse) Anti‐IL13 or anti‐IL4 agents vs placebo | no estimate extracted | 14 studies · 6251 participants | Moderate Downgraded: imprecision, inconsistency, indirectness |
Adverse events (any) Anti‐IL13 or anti‐IL4 agents vs placebo | OR 1.16 [1.04, 1.3] | 18 studies · 7419 participants | High |
Time off work or study Anti‐IL13 or anti‐IL4 agents vs placebo | no estimate extracted | NR | No studies |
Other secondary and post hoc exploratory outcomes
Population: children and adults with asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change from baseline in pre‐bronchodilator FEV1 | no estimate extracted | 13 studies · 4829 participants | Moderate Downgraded: imprecision, inconsistency |
Change from baseline in FENO (ppb) | no estimate extracted | 11 studies · 3577 participants | Moderate Downgraded: imprecision, inconsistency |
Change from baseline in blood eosinophils (cells x 10*9/L) | no estimate extracted | 6 studies · 2598 participants | High |
Change from baseline in Periostin (ng/mL) | no estimate extracted | 2 studies · 2106 participants | Low Downgraded: imprecision, inconsistency |
Percentage reduction from baseline in maintenance OCS dose | no estimate extracted | 2 studies · 350 participants | Low Downgraded: imprecision, inconsistency |
Post hoc exploratory endpoint: Exacerbation requiring hospitalisation/ED/OCS (rate ratio) | Rate ratio 0.71 [0.65, 0.77] | 7 studies · 6998 participants | Low Downgraded: imprecision, inconsistency |